(When excluding one-time divestment contributions and last year's Covid antibody revenue, Lilly's sales rose 22% on an annual basis.) Eli Lilly shares soared more than 16% to a new all-time high during Tuesday's session. LLY YTD mountain Eli Lilly's stock performance so far in 2023. Eli Lilly now expects adjusted earnings per share between $9.70 and $9.90, up significantly from the old guidance between $8.65 and $8.85. For its part, Eli Lilly is also studying Mounjaro's impact on other health outcomes including cardiovascular events.

---

Persons: Eli Lilly, Mounjaro, —, Jim Cramer's, Jim, Lilly's, Cheplapharm —, Lilly, Anat Ashkenazi, Ashkenazi, Eli Lilly's, Lilly Diabetes, Michael Mason, Mason, Verzenio, Trulicity, we've, David Ricks, Jim Cramer, Cristina Arias Organizations: Novo Nordisk, U.S, Amphastar Pharmaceuticals, Management, CNBC, Company, Pharmaceutical Locations: Indianapolis, North Carolina, U.S, Trulicity, Danish, Novo, Alcobendas, Madrid, Spain